Trial Profile

A Phase 1, Multicenter, Open-label, Dose- Escalation, Safety, Pharmacodynamic, Pharmacokinetic Study of Q702 with a Cohort Expansion At the RP2D in Patients with Advanced Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adrixetinib (Primary)
Indications Colon cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
Focus Adverse reactions; First in man; Pharmacokinetics
Sponsors Qurient Co

Most Recent Events

30 Apr 2025 Results (n=51; as of 11 Jun 2024) presented at the 116th Annual Meeting of the American Association for Cancer Research
27 Nov 2024 Status changed from recruiting to active, no longer recruiting.
29 Dec 2023 Planned End Date changed from 18 Nov 2023 to 28 Feb 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com